NEW YORK, Sept. 24, 2023 /PRNewswire/ -- The thyroid gland disorder treatment market is expected to grow by USD 868.87 million from 2022 to 2027. In addition, the growth momentum of the market will progress at a CAGR of 5.33% during the forecast period, according to Technavio. The rise in thyroid treatment awareness programs globally is notably driving the thyroid gland disorder treatment market. However, factors such as High entry barriers by established players may impede market growth. The market is segmented by type (hypothyroidism and hyperthyroidism), distribution channel (offline and online), and geography (North America, Europe, Asia, and the Rest of World (ROW)). We provide a detailed analysis of 20 companies operating in the thyroid gland disorder treatment market including Abbott Laboratories, AbbVie Inc., Alvogen Iceland ehf, Amgen Inc., Exelixis Inc., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, IBSA Institute Biochimique SA, JEROME STEVENS PHARMACEUTICALS INC., Lannett Co. Inc., Lupin Ltd., Mayne Pharma Group Ltd., Merck KGaA, Novartis AG, Pfizer Inc., Piramal Enterprises Ltd., RLC Labs Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., and Viatris Inc..The report offers an up-to-date analysis of the market, and to know the exact growth variance and the Y-O-Y growth rate, Request a Free Sample Report.

Thyroid Gland Disorder Treatment Market 2023-2027: Company Analysis

• Abbott Laboratories - The company offers different types of thyroid gland disorder treatment such as Thyronorm, Thyrocab, Thyrocal D3, and others. 

This report provides a full list of key companies, their strategies, and the latest developments. Buy Now for detailed company information

Thyroid Gland Disorder Treatment Market 2023-2027: Segmentation

Type

• The market share growth by the hypothyroidism segment will be significant during the forecast period. Hypothyroidism or underactive thyroid is a condition in which the thyroid gland is unable to produce significant amounts of important thyroid hormones. Over time, untreated hypothyroidism can lead to the development of various health problems, such as obesity, infertility, joint pain, and cardiovascular disease. This disorder affects women more often than men. However, the geriatric age group is also susceptible to hypothyroidism. Growing awareness of timely diagnosis of chronic diseases is driving demand for effective treatment options, which is driving growth in sales of commercially available drugs to treat hypothyroidism. Hence, these factors are expected to drive segment growth during the forecast period.

Geography 

• North America is estimated to account for 37% of the global market during the forecast period. This region dominates the thyroid disorders treatment market with the US and Canada being the major revenue generators. In the region, the increasing prevalence of thyroid disorders and increasing awareness about timely diagnosis and treatment are driving the market growth. Associations such as the American Association of Clinical Endocrinologists (AACE), the American Thyroid Association (ATA), and the Human Growth Foundation (HGF) are involved in raising awareness of the disorders thyroid and treatment options available in the area. For example, in January 2020, coinciding with Thyroid Awareness Month, AACE launched the UP To Here campaign. Hence, these factors are expected to drive market growth in the region during the forecast period. 

Learn about the contribution of each segment summarized in concise infographics and thorough descriptions. View PDF Sample Report

Thyroid Gland Disorder Treatment Market 2023-2027: Key Highlights

• Historic Market Size 2017-2021
• CAGR of the market during 2023-2027
• Detailed information on factors that will assist thyroid gland disorder treatment market growth during the next five years
• Estimation of the thyroid gland disorder treatment market size and its contribution to the parent market
• Forecasts on upcoming trends and changes in consumer behavior
• The growth of the thyroid gland disorder treatment market
• Analysis of the competitive landscape and detailed information on companies
• Comprehensive details of factors that will impede the growth of thyroid gland disorder treatment market companies

Related Reports:

The laparoscopic devices market is estimated to grow by USD 4,396.16 million at a CAGR of 8.11% between 2022 and 2027. 

The cranial orthoses market is estimated to grow by USD 136.94 million at a CAGR of 9.22% between 2022 and 2027.

ToC:

Executive Summary

Market Landscape

Market Sizing

Historic Market Sizes

Five Forces Analysis

Market Segmentation by Type

Market Segmentation by Distribution Channel

Market Segmentation by Geography

Customer Landscape

Geographic Landscape

Drivers, Challenges, & Trends

Company Landscape

Company Analysis

Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/the-thyroid-gland-disorder-treatment-market-to-grow-by-usd-868-87-million-from-2022-to-2027--abbott-laboratories-abbvie-inc-alvogen-iceland-ehf-and-more-among-key-companies--technavio-301936306.html

SOURCE Technavio